GB2013691A - IgG Preparations - Google Patents

IgG Preparations

Info

Publication number
GB2013691A
GB2013691A GB7903836A GB7903836A GB2013691A GB 2013691 A GB2013691 A GB 2013691A GB 7903836 A GB7903836 A GB 7903836A GB 7903836 A GB7903836 A GB 7903836A GB 2013691 A GB2013691 A GB 2013691A
Authority
GB
United Kingdom
Prior art keywords
igg
milk
cows
preparation
passive immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB7903836A
Other versions
GB2013691B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stolle Research and Development Corp
Original Assignee
Stolle Research and Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stolle Research and Development Corp filed Critical Stolle Research and Development Corp
Publication of GB2013691A publication Critical patent/GB2013691A/en
Application granted granted Critical
Publication of GB2013691B publication Critical patent/GB2013691B/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

There is disclosed an immune gammaglobulin (IgG) preparation for the treatment and prevention of rheumatoid arthritis. The treatment involves passive immunization against a mixed spectrum of infectious bacteria which reside in the human gastrointestinal tract. The passive immunization may be accomplished by oral ingestion of IgG immunoglobulin obtained from the milk of cows that have been immunized against a specific spectrum of bacterial types. A unique combination of bacterial species is formulated into a vaccine which may then be used to immunize dairy cattle. Preferably, the IgG preparation is obtained from the milk of the immunized cows.
GB7903836A 1978-02-06 1979-02-02 Immune gammaglobulin preparation for the treatment of rheumatoid arthritis Expired GB2013691B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87514078A 1978-02-06 1978-02-06

Publications (2)

Publication Number Publication Date
GB2013691A true GB2013691A (en) 1979-08-15
GB2013691B GB2013691B (en) 1982-08-18

Family

ID=25365266

Family Applications (1)

Application Number Title Priority Date Filing Date
GB7903836A Expired GB2013691B (en) 1978-02-06 1979-02-02 Immune gammaglobulin preparation for the treatment of rheumatoid arthritis

Country Status (10)

Country Link
JP (1) JPS54113425A (en)
CH (1) CH651210A5 (en)
DE (1) DE2904044C2 (en)
DK (1) DK158138C (en)
FR (1) FR2416015A1 (en)
GB (1) GB2013691B (en)
HK (1) HK30283A (en)
IT (1) IT1116524B (en)
NL (1) NL7900766A (en)
SE (1) SE448344B (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0064103A1 (en) * 1981-04-28 1982-11-10 The Stolle Research And Development Corporation Method of obtaining an anti-inflammatory bovine milk
EP0127712A1 (en) * 1983-06-07 1984-12-12 The Stolle Research And Development Corporation Deodorant containing bacterial antibodies
EP0143345A2 (en) * 1983-10-27 1985-06-05 The Stolle Research And Development Corporation Use of hyperimmune milk for the manufacture of a medicament for the treatment of cardio-vascular diseases or for lowering lipid bloodstream levels
GB2160771A (en) * 1984-06-28 1986-01-02 Lion Corp Composition for oral application
US4732757A (en) * 1978-02-06 1988-03-22 Stolle Research And Development Corporation Prevention and treatment of rheumatoid arthritis
EP0300102A1 (en) * 1987-07-21 1989-01-25 The Stolle Research And Development Corporation Improved method of obtaining immune regulatory factors by mammal immunization
USRE33565E (en) * 1978-02-06 1991-04-02 Stolle Research And Development Corporation Prevention and treatment of rheumatioid arthritis
WO2000062806A1 (en) * 1999-04-19 2000-10-26 Richard Weisbart Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
WO2002026258A2 (en) * 2000-09-28 2002-04-04 Research Corporation Technologies, Inc. Treatment of immune-mediated diseases by oral administration of plasma fractions
WO2002078742A2 (en) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Methods and compositions for treatment of immune dysfunction disorders
WO2002078741A2 (en) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Methods and compositions for modulating the immune system of animals

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE14269T1 (en) * 1981-02-26 1985-08-15 Unilever Nv METHOD AND DEVICE FOR RECOVERING IMMUNOGLOBULINES.
JP2561234B2 (en) * 1981-05-12 1996-12-04 スト−ル・リサ−チ・アンド・デイベロップメント・コ−ポレ−ション Anti-inflammatory agent
JPS58154513A (en) * 1982-03-09 1983-09-14 Sendai Biseibutsu Kenkyusho Preventive and remedying drug
JP2664906B2 (en) * 1987-08-13 1997-10-22 ストール・リサーチ・アンド・デイベロップメント・コーポレーション Improved mammalian immunization
JP4960632B2 (en) * 2006-01-10 2012-06-27 学校法人北里研究所 Composition for treating and preventing herpes simplex virus infection comprising immune milk composition as active ingredient
JP5361132B2 (en) * 2006-03-10 2013-12-04 国立大学法人信州大学 An oral immunomodulator containing immunoglobulin G, a method for producing the same, and a food or drink comprising the oral immunomodulator
JP2008179572A (en) * 2007-01-25 2008-08-07 Shinshu Univ IMMUNOGLOBULIN Fc FRAGMENT RECEPTOR PROTEIN AND/OR PRODUCTION INHIBITOR OF IMMUNOGLOBULIN Fc FRAGMENT RECEPTOR LIKE PROTEIN, AND USE OF THE SAME

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1617538C3 (en) * 1965-10-24 1979-10-04 The Immune Milk Co. Of America, Inc., Cincinnati, Ohio (V.St.A.) Method of making tetanus antitoxin
DE1617769A1 (en) * 1967-06-10 1971-04-01 Rehm Eberhard Process for the production of milk containing specific antibodies and preparations made therefrom
JPS5136326A (en) * 1974-09-24 1976-03-27 Komatsu Seiren Co SEIKEIGORU FUBOORU
JPS5837285B2 (en) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ It is very difficult to understand the situation.
JPS521014A (en) * 1975-06-17 1977-01-06 Stolle Res & Dev Pharmaceutically acceptable carrier containing milk immunoglobulin
JPS5381613A (en) * 1976-12-28 1978-07-19 Green Cross Corp:The Remedies for enteral infection diseases
CH627079A5 (en) * 1977-04-15 1981-12-31 Nestle Sa Process for preparing a protein concentrate containing immunological factors of milk origin

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33565E (en) * 1978-02-06 1991-04-02 Stolle Research And Development Corporation Prevention and treatment of rheumatioid arthritis
US4732757A (en) * 1978-02-06 1988-03-22 Stolle Research And Development Corporation Prevention and treatment of rheumatoid arthritis
EP0064103A1 (en) * 1981-04-28 1982-11-10 The Stolle Research And Development Corporation Method of obtaining an anti-inflammatory bovine milk
EP0127712A1 (en) * 1983-06-07 1984-12-12 The Stolle Research And Development Corporation Deodorant containing bacterial antibodies
EP0143345A2 (en) * 1983-10-27 1985-06-05 The Stolle Research And Development Corporation Use of hyperimmune milk for the manufacture of a medicament for the treatment of cardio-vascular diseases or for lowering lipid bloodstream levels
DE3439345A1 (en) * 1983-10-27 1986-04-24 Stolle Research & Development Corp., Cincinnati, Ohio USE OF HYPERIMMUNE MILK FOR TREATING ANIMALS AND HUMANS
EP0143345A3 (en) * 1983-10-27 1987-09-30 The Stolle Research And Development Corporation Use of hyperimmune milk for treating disorders of the vascular and pulmonary systems in mammals
EP0380032A1 (en) * 1983-10-27 1990-08-01 The Stolle Research And Development Corporation Use of milk for the manufacture of a hyperimmune milk composition for treating disorders of the pulmonary system in mammals
GB2160771A (en) * 1984-06-28 1986-01-02 Lion Corp Composition for oral application
US4714612A (en) * 1984-06-28 1987-12-22 Lion Corporation Composition for oral application
EP0300102A1 (en) * 1987-07-21 1989-01-25 The Stolle Research And Development Corporation Improved method of obtaining immune regulatory factors by mammal immunization
WO2000062806A1 (en) * 1999-04-19 2000-10-26 Richard Weisbart Treatment of adult rheumatoid arthritis by oral administration of pooled human immunoglobulin and an antacid
WO2002026258A2 (en) * 2000-09-28 2002-04-04 Research Corporation Technologies, Inc. Treatment of immune-mediated diseases by oral administration of plasma fractions
WO2002026258A3 (en) * 2000-09-28 2002-10-24 Res Corp Technologies Inc Treatment of immune-mediated diseases by oral administration of plasma fractions
WO2002078742A2 (en) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Methods and compositions for treatment of immune dysfunction disorders
WO2002078741A2 (en) * 2001-01-30 2002-10-10 The Lauridsen Group, Incorporated Methods and compositions for modulating the immune system of animals
WO2002078742A3 (en) * 2001-01-30 2003-03-13 Lauridsen Group Inc Methods and compositions for treatment of immune dysfunction disorders
WO2002078741A3 (en) * 2001-01-30 2003-05-01 Lauridsen Group Inc Methods and compositions for modulating the immune system of animals

Also Published As

Publication number Publication date
FR2416015B1 (en) 1983-06-17
DE2904044C2 (en) 1986-02-06
DK49479A (en) 1979-08-07
JPH0160455B2 (en) 1989-12-22
IT1116524B (en) 1986-02-10
IT7947888A0 (en) 1979-02-05
JPS54113425A (en) 1979-09-05
DK158138B (en) 1990-04-02
GB2013691B (en) 1982-08-18
NL7900766A (en) 1979-08-08
SE448344B (en) 1987-02-16
DK158138C (en) 1990-08-27
HK30283A (en) 1983-09-02
CH651210A5 (en) 1985-09-13
FR2416015A1 (en) 1979-08-31
DE2904044A1 (en) 1979-08-30
SE7900798L (en) 1979-08-07

Similar Documents

Publication Publication Date Title
GB2013691A (en) IgG Preparations
Mietens et al. Treatment of infantile E. coli gastroenteritis with specific bovine anti-E. coli milk immunoglobulins
Tsubokura et al. Oral administration of antibodies as prophylaxis and therapy in Campylobacter jejuni‐infected chickens
CA1276884C (en) Protein antibody derived from serum of a bovid
US4341763A (en) Methods of vaccinating humans against rotavirus infection
Ebina Prophylaxis of rotavirus gastroenteritis using immunoglobulin
RU93058676A (en) ORAL TREATMENT OF HELICOBACTERIAL INFECTION
EP0143445A3 (en) Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
ES2007720A6 (en) Vaccine and method of preparation.
CA2022420A1 (en) Escherichia coli vaccine
Casswall et al. Treatment of Helicobacter pylori infection in infants in rural Bangladesh with oral immunoglobulins from hyperimmune bovine colostrum
IE940698L (en) Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
Boesman-Finkelstein et al. Bovine lactogenic immunity against cholera toxin-related enterotoxins and Vibrio cholerae outer membranes
DK398683D0 (en) PROCEDURE FOR MANUFACTURING ANTIBODIES
Wilson et al. Immunity to Escherichia coli in pigs. The role of milk in protective immunity to E. coli enteritis
DE69823638D1 (en) Oral product for the prevention and treatment of contagious gastroenteritis in calves
NZ299579A (en) ue of hyperimmune milk to restore decreasing physiologic function
CA2047843A1 (en) Method and product for the treatment of gastric disease
AU6435596A (en) Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
NO771289L (en) PRODUCT FOR PROPHYLAXIS AND THERAPY OF GASTRO-ENTERITIS
Reynolds et al. Humoral immunity in the ewe 3. The influence of adjuvants and immunisation regimes on Immune reactivity in the breeding ewe and her progeny
Kaijser Peroral Immunization of Healthy Adults with Live Escherichia coli O4K12 Bacteria: Antibody Response as Measured in Serum and Secretions
RU2090193C1 (en) Method for producing specific lactoglobulin
Hanson et al. Implications for Immunisation: The Milk IgA Antibody Response to Live and Inactivated Polio Virus Vaccines
RU93052669A (en) METHOD FOR PRODUCING SPECIFIC LACTOGLOBULIN

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 19990201